• Molecular NameSucralfate
  • Synonymsucralfate
  • Weight1599.13
  • Drugbank_IDDB00364
  • ACS_NO54182-58-0
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)N/A
  • pkaN/A
  • LogD (pH=7, predicted)N/A
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)N/A
  • LogSw (predicted, AB/LogsW2.0)N/A
  • Sw (mg/ml) (predicted, ACD/Labs)N/A
  • No.of HBond DonorsN/A
  • No.of HBond AcceptorsN/A
  • No.of Rotatable BondsN/A
  • TPSAN/A
  • StatusFDA approved
  • AdministrationOral, suspension, rectal suspension
  • PharmacologyAn oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.
  • Absorption_valueN/A
  • Absorption (description)Minimally absorbed from the gastrointestinal tract (up to 5% of the disaccharide component and less than 0.02% of aluminum).
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmGI; liver: unknown
  • Half lifeN/A
  • Excretionfeces, urine
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThere is limited experience in humans with overdosage of sucralfate. Sucralfate is only minimally absorbed from the gastrointestinal tract and thus risks associated with acute overdosage should be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50>8000 mg/kg